menu
    • menu
    [{"orgOrder":0,"company":"Qlaris Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qlaris Bio Enrolls First Patient in Phase 1\/2 Studies of QLS-101 in Patients with Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"QLS-101","moa":"KATP Channel","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Qlaris Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Qlaris Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qlaris Bio.."},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan\u00ae Ophthalmic Solution in the United States","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Apotex Fermentation Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fer.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Brimonidine Tartrate\/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertension, Expanding Leading Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Sandoz B2B \/ ","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Amring Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Timolol Maleate","moa":"ADRB","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amring Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amring Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amring Pha.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen EMEA Announces RWD on Taptiqom","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Timolol Maleate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."}]

    Find Clinical Drug Pipeline Developments & Deals for Bimatoprost / timolol

    Menu

    Bimatoprost / timolol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glenmark Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate

                            Details : Combigan-Generic (brimonidine tartrate/timolol maleate) is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated IOP.

                            Brand Name : Combigan-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2024

                            Lead Product(s) : Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Santen Pharmaceutical

                            Japan arrow
                            Formnext Forum
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafluprost,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open...

                            Details : STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.

                            Brand Name : STN1011101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 08, 2023

                            Lead Product(s) : Tafluprost,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amring Pharma

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Amring Pharma

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amring Pharmaceuticals Inc. Announces the Launch of Timolol Maleate Ophthalmic Solution, USP 0.5%

                            Details : Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for treatment of elevated intraocular pressure in patients with ocular hyp...

                            Brand Name : Timolol Maleate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 23, 2022

                            Lead Product(s) : Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sandoz B2B

                            Switzerland arrow
                            Formnext Forum
                            Not Confirmed

                            Sandoz B2B

                            Switzerland arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor :

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sandoz Launches Generic Brimonidine Tartrate/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertensi...

                            Details : Brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% is an alpha-adrenergic receptor agonist with a betaadrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with ocular hypertensi...

                            Brand Name : Brimonidine Tartarate/Timolol Maleate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 14, 2022

                            Lead Product(s) : Brimonidine Tartrate,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor :

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apotex Fermentation Inc.

                            Canada arrow
                            Formnext Forum
                            Not Confirmed

                            Apotex Fermentation Inc.

                            Canada arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Apotex Corp. Launches First-to-Market Authorized Generic Version of Combigan® Ophthalmic Solution in the Unit...

                            Details : Company launched Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution which is a generic version of Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 19, 2022

                            Lead Product(s) : Brimonidine Tartrate,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Qlaris Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Qlaris Bio

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QLS-101,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101 in Patients with Glaucoma

                            Details : QLS-101 is a novel adenosine triphosphate (ATP)-sensitive potassium (KATP) channel modulator administered as a topical eyedrop. QLS-101 specifically lowers EVP, a key determinant of IOP, or fluid pressure in the eye, which can be elevated in individuals ...

                            Brand Name : QLS-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2021

                            Lead Product(s) : QLS-101,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Santen Pharmaceutical

                            Japan arrow
                            Formnext Forum
                            Not Confirmed

                            Santen Pharmaceutical

                            Japan arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafluprost,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Santen EMEA Announces RWD on Taptiqom

                            Details : Taptiqom (tafluprost/timolol) is a PTGFR agonist which is being developed for statistical and clinically significant intraocular pressure (IOP) reductions in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).

                            Brand Name : Taptiqom

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 26, 2020

                            Lead Product(s) : Tafluprost,Timolol Maleate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4